Clinical Trials | November 29, 2023
Roche expands hepatitis diagnostics portfolio
Almost 300 million people globally have chronic hepatitis B
Almost 300 million people globally have chronic hepatitis B
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
Roche and its subsidiary TIB Molbiol have developed three different LightMix Modular Virus kits for the detection of the virus
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
Subscribe To Our Newsletter & Stay Updated
